Ergoteles’s Stoke Therapeutics STOK Stock Holding History

Ergoteles’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,871	Closed	-$141K	–	1502
2023 Q1	$141K	Sell	16,871 -10,537	-38%	-$95.1K	0.01%	1068
2022 Q4	$253K	Buy	+27,408	New	+$285K	0.01%	974

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ergoteles's STOK Position: Q2 2023 in Review

Ergoteles sold out of Stoke Therapeutics (STOK) in Q2 2023, closing a stake of 16,871 shares — an estimated $141K sold.

Ergoteles first reported a position in STOK in Q4 2022 and held it in 2 quarters. The position peaked at $253K in Q4 2022. 100 funds tracked by Wall St. Rank hold STOK as of Q2 2023.

Ergoteles reported no remaining Stoke Therapeutics position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 16,871 Stoke Therapeutics shares in Q2 2023, an estimated $141K.
Ergoteles first reported a position in Stoke Therapeutics in Q4 2022 and held it in 2 quarters.
Ergoteles's Stoke Therapeutics position peaked at $253K in Q4 2022.
100 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.